Seehra Jasbir 4

What Happened

• Jasbir Seehra, CEO of Keros Therapeutics (KROS), sold 7,015 shares on 2026-02-19 at $16.17 per share, for proceeds of approximately $113,433. The filing reports this as a sale (code S).

Key Details

• Transaction date: 2026-02-19; Price: $16.17 per share; Shares sold: 7,015; Total: ~$113,433.
• Shares owned after the transaction: Not specified in the submitted excerpt of the filing.
• Footnote: The sale was part of the issuer’s automatic "sell-to-cover" policy to satisfy tax withholding on vested restricted stock units (RSUs); the sales were automatic and not at the insider’s discretion.
• Filing timeliness: Reported on 2026-02-20 for a 2026-02-19 transaction — appears to have been filed promptly.

Context

• This was a sale tied to tax withholding for RSU vesting (routine administrative transaction), not an open-market discretionary sale intended to express a view on the stock.
• For retail investors, routine sell-to-cover transactions are common and generally less informative about an insider’s sentiment than voluntary open-market purchases.